| calcium |
drug |
21 |
9 |
Ca, Ca+2, Ca2+, Calcium, Calcium ion, [Ca(t)] |
| calcium channel |
drug |
2 |
2 |
|
| calcium chloride |
drug |
5 |
4 |
CaCl2 |
| California |
cohort |
3 |
1 |
|
| Calm1 |
gene |
4 |
2 |
calmodulin |
| calmodulin |
drug |
2 |
3 |
|
| caloric restriction |
phenotype |
5 |
4 |
CR |
| calretinin |
drug |
2 |
5 |
CALB2, calretinin protein |
| CAMK2A |
gene |
3 |
2 |
CaMKII, CaMKIIα, Calcium/calmodulin-dependent protein kinase II alpha, Camk2a, CamkII-α, αCaMKII |
| CAMK2D |
gene |
3 |
1 |
CaMKIIδ, calcium/calmodulin-dependent protein kinase type II Δ chain subunit |
| CamKII |
drug |
4 |
2 |
CAMK2, CaMKII, CaMKII family, Calcium/calmodulin-dependent protein kinase II, calcium/calmodulin-dependent protein kinase II, type II CaMK |
| CAMKK2 |
gene |
3 |
2 |
Ca2+/calmodulin-dependent protein kinase kinase β, CaMKKb, CaMKKβ |
| cAMP |
drug |
15 |
12 |
cyclic AMP, cyclic adenosine 3′,5′-monophosphate, cyclic adenosine monophosphate |
| Canada |
cohort |
6 |
2 |
|
| cancer |
phenotype |
88 |
46 |
any type of cancer, cancer, cancer risk, cancer-related networks, cancers, carcinogenesis, malignant neoplasms, multiple types of cancer, some types of cancer, tumor, various cancers |
| cancer development |
phenotype |
3 |
2 |
|
| cancer phenotypes |
phenotype |
2 |
1 |
cancer |
| cancer risk |
phenotype |
4 |
2 |
|
| candidate gene association studies |
cohort |
2 |
— |
|
| candidate genes |
cohort |
26 |
53 |
genes |
